| Project/Area Number |
20790562
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
TANNO Sachie Asahikawa Medical College, 大学病院, 医員 (80455724)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2008: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | チアゾリジン誘導体 / 肺がん / collagen XVIII / PPARgamma / 血管新生抑制因子 / PPAR / VEGF / VEGFR / 肺癌 / AKT |
|---|
| Research Abstract |
Thiazolidinedione (TZD) use in patients with diabetes was specifically associated with reduced risk of lung cancer. Since collagen XVIII is one of the strongest predictors of outcome in patients with lung cancer, we examined the effects of TZD on expression of collagen XVIII in human non-small lung cancer (NSCLC) cells. The present results results suggest for the first time that TZDs reduced expression of collagen XVIII in NSCLC, which may help us understand the mechanism why TZDs use has chemopreventive action.
|
